In April 2005, the FDA initiated more stringent guidance for microbial ingress testing on Needleless valves. These new recommendations are highlighted below:
Static insertion of luer / syringe for more than one hour Requires repeated insertions of the luer / syringe. Valve inoculations should approximate # of daily interactions with site More than 5 valve inoculations per day 10 - 20 microliters of inoculant Staphylococcus aureus or epidermis as inoculants Allow inoculant to dry for > 1 minute Use 70% IPA to disinfect
Please make sure to ask the manufacturer of your needleless valve whether they qualify their valve to the New FDA standards. Here at Maximus Medical, we made sure our MaxPlus featuring Tru-Swab Technology connector was tested to (and beyond) the new FDA standards at an independent lab2; the MaxPlus® produced zero failures and was clearly the clinically superior valve when tested to it’s competitors. The study can be found here.
1. FDA, US Department of Health and Services: "Guidance for industry and FDA Staff, Intravascular Administration Sets Pre-Market Notification Submissions (510K)", April 15,2005.
2. In vitro testing per established protocol conducted by LGGS Laboratory Services, Anaheim, CA.
Take a Look at the New FDA Recommendations
for Microbial Ingress Testing...
Repeat insertions with same luer
Recommends static insertion ≥ 1 hour
Valve inoculations should approximate # of daily
interactions with site
> 5 valve inoculations per day
10-20 microliters of inoculant
Staphylococcus aureus / epidermis as inoculants
Allow inoculant to dry for > 1 minute
Use 70% IPA to disinfect
Does your current valve's microbial study meet the above requirements? Take a Look at the New FDA Recommendations
for Microbial Ingress Testing...
If not, you may want to take a closer look at one that does: the MaxPlus Tru-swabTM IV connector...
*Does not advertise Microbial Challenge Study
MaxPlus and Tru-Swab are trademarks of Medegen MMS
The MaxPlus is the fastest growing needleless connector on the market today.
As evidence to its success the MaxPlus is being utilized in a number of facilities who in 2006 were awarded Honor Roll status by the U.S. News and World Report as 'America's Best Hospitals." The nation's top facilities are using the MaxPlus for two main reasons; it significantly lowers Catheter Related Blood Stream infections CRBSIs and catheter line occlusions. Reducing these two complications improves patient outcomes.